Our results suggest that AZD5363, when combined with doxorubicin, allows a cooperative sensitization of cancer cells to the latter molecule through the inhibition of Akt and mTOR signaling pathways, downregulation of key inhibitors of apoptosis as well as nuclear localization of tumor suppressors such as FOXO1 (forkhead box protein O1) and p53 (tumor protein P53). Here, AKT1 is linked to cancer.